The Swedish-British pharmaceutical giant AstraZeneca, attributed to owners of the parent company, decreased in January-September 2018 by 34% compared to $ 1.12 billion.
The diluted earnings per share was $ 0.88 compared to $ 1.34 in the same period of 2017. Operating profit was down 23% to $ 2.3 billion, revenue – 6% to $ 15.673 billion, reports PRIME.
In the third quarter, AstraZeneca reduced its net profit by 37% annually to $ 431 million. The diluted earnings per share amounted to $ 0.34, down from $ 0.54 in the third quarter of 2017. Operating profit fell 26% to $ 851 million, while revenues fell 14% to $ 5.34 billion.
By the end of the year, the company predicts sales growth of 1-3%, and earnings per share range from $ 3.3-3.5.